Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. A 6-year, case-control study.

Completed

• Conditions: Peripheral psoriatic arthritis; Musculoskeletal Diseases; arthritis

• Registration Number: ISRCTN45507228
• Lead Sponsor: Hospital of Prato (Italy)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2007-02-26
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 400

Inclusion Criteria

Case patients: consecutive new outpatients with peripheral psoriatic arthritis requiring second-line drugs
Controls: consecutive new outpatients with rheumatoid arthritis

Exclusion Criteria

Patients with inflammatory spinal pain at presentation or during the disease course, or meeting the modified New York criteria for ankylosing spondylitis, and those with contraindications to the use of traditional DMARDs and anti-TNFa drugs.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Modified American College of Rheumatology (ACR) criteria for clinical remission

Secondary Outcome Measures

Name	Time	Method
Duration of clinical remission during treatment and after therapy interruption, to evaluate the ACR 20, 50, 70 response rates at the end of follow up, and to evaluate the correlation between initial clinical and laboratory variables and the frequency of remissions.